NICENEC phase 2 trial of nivolumab and platinum-doublet chemotherapy in untreated advanced G3 Neuroendocrine Neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin: Efficacy by differentiation, KI67 index and primary tumor site

被引：0

作者：

Riesco-Martinez, M. D. C. ^{[1
]}

Capdevila, J. ^{[2
]}

Alonso, V ^{[3
]}

Jimenez-Fonseca, P. ^{[4
]}

Teule, A. ^{[5
]}

Grande, E. ^{[6
]}

Sevilla, I ^{[7
]}

Vinuales M, Benavent ^{[8
]}

Alonso-Gordoa, T. ^{[9
]}

Custodio, A. ^{[10
]}

Hernando, J. ^{[2
]}

Garcia-Carbonero, R. ^{[1
]}

机构：

[1] UCM, Hosp Univ 12 Octubre, Med Oncol Dept, Imas12, Madrid, Spain

[2] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Med Oncol Dept, Barcelona, Spain

[3] Hosp Univ Miguel Servet, Inst Aragones Invest Sanitaria, Med Oncol Dept, Zaragoza, Spain

[4] Hosp Univ Cent Asturias, ISPA, Med Oncol Dept, Oviedo, Spain

[5] Inst Catala Oncol ICO IDIBELL, Lhospitalet Llobregat, Spain

[6] MD Anderson Canc Ctr, Med Oncol Dept, Madrid, Spain

[7] Hosp Univ Virgen de la Victoria Malaga, IBIMA, Invest Clin & Traslac Canc, Med Oncol Dept, Malaga, Spain

[8] Univ Hosp Virgen del Rocio, Inst Biomed Sevilla IBIS, Med Oncol Dept, Seville, Spain

[9] Hosp Univ Ramon y Cajal, Med Oncol, Madrid, Spain

[10] Hosp Univ La Paz, Med Oncol Dept, Madrid, Spain

来源：

JOURNAL OF NEUROENDOCRINOLOGY | 2022年 / 34卷

关键词：

grade 3 neuroendocrine neoplasm; nivolumab; gastroenteropancreatic;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

I28

引用

页码：190 / 190

页数：1

共 4 条

[1] Final overall survival results from the NICE-NEC trial (GETNE-T1913): A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in untreated advanced G3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin
Riesco Martinez, M. C.
Capdevila Castillon, J.
Alonso, V.
Jimenez-Fonseca, P.
Teule, A.
Grande, E.
Sevilla, I.
Benavent, M.
Alonso-Gordoa, T.
Custodio, A.
Anton Pascual, B.
Hernando, J.
Polo, E.
Castillo Trujillo, O. A.
Garcia-Carbonero, R.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S769 - S769
[2] Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913)
Riesco-Martinez, M. C.
Capdevila, J.
Alonso, V.
Jimenez-Fonseca, P.
Teule, A.
Grande, E.
Sevilla, I.
Benavent Vinuales, M.
Alonso-Gordoa, T.
Custodio, A.
Hernando, J.
Polo, E.
Castillo Trujillo, O. A.
Garcia-Carbonero, R.
ANNALS OF ONCOLOGY, 2021, 32 : S908 - S909
[3] Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)
Riesco-Martinez, Maria Carmen
Capdevila, Jaume
Alonso, Vicente
Jimenez-Fonseca, Paula
Teule, Alex
Grande, Enrique
Sevilla, Isabel
Benavent, Marta
Alonso-Gordoa, Teresa
Custodio, Ana
Anton-Pascual, Beatriz
Hernando, Jorge
Polo, Eduardo
Castillo-Trujillo, Oscar Alfredo
Lamas-Paz, Arantza
Teijo, Ana
Rodriguez-Gil, Yolanda
Soldevilla, Beatriz
Garcia-Carbonero, Rocio
NATURE COMMUNICATIONS, 2024, 15 (01)
[4] NICE-NEC, a phase II study of platinum-doublet chemotherapy in combination with nivolumab as first-line treatment in subjects with unresectable, locally advanced or metastatic grade 3 neuroendocrine neoplasms (NENs) of the gastroenteropancreatic tract or of unknown origin. GETNE-T1913
Riesco Martinez, M. C.
Capdevila, J.
Alonso, V.
Teule, A.
Grande, E.
Jimenez-Fonseca, P.
Benavent, M.
Alonso Gordoa, T.
Custodio, A.
Hierro Carbo, C.
Lopez, C.
Sevilla Garcia, I.
Garcia-Carbonero, R.
ANNALS OF ONCOLOGY, 2020, 31 : S783 - S783

← 1 →